1. Home
  2. PLG vs ARMP Comparison

PLG vs ARMP Comparison

Compare PLG & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Platinum Group Metals Ltd. (Canada)

PLG

Platinum Group Metals Ltd. (Canada)

HOLD

Current Price

$1.59

Market Cap

193.1M

Sector

N/A

ML Signal

HOLD

Logo Armata Pharmaceuticals Inc.

ARMP

Armata Pharmaceuticals Inc.

HOLD

Current Price

$5.41

Market Cap

199.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLG
ARMP
Founded
2000
N/A
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
193.1M
199.7M
IPO Year
2002
1996

Fundamental Metrics

Financial Performance
Metric
PLG
ARMP
Price
$1.59
$5.41
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$15.00
AVG Volume (30 Days)
1.3M
93.2K
Earning Date
04-10-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.18
$2.86
52 Week High
$4.04
$14.98

Technical Indicators

Market Signals
Indicator
PLG
ARMP
Relative Strength Index (RSI) 57.33 55.53
Support Level $1.56 $5.12
Resistance Level $1.65 $5.63
Average True Range (ATR) 0.08 0.47
MACD -0.00 0.08
Stochastic Oscillator 59.62 84.37

Price Performance

Historical Comparison
PLG
ARMP

About PLG Platinum Group Metals Ltd. (Canada)

Platinum Group Metals Ltd is a development-stage company, conducts work on mineral properties it has staked or acquired by way of option agreements in the Republic of South Africa. Key metals of economic interest on the company's mineral properties include platinum, palladium, rhodium, gold, copper, and nickel. The company operates in one segment, the development of the Waterberg Project in South Africa, and geographically in Canada and South Africa.

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.

Share on Social Networks: